U.S. Agency places order for PExA instrument upgrade
The National Institute for Occupational Safety and Health (NIOSH), which was PExA’s first customer in the United States, has placed an order for an upgrade of their PExA 2.0 instrument.
The U.S. federal agency NIOSH, which conducts research and provides recommendations to prevent work-related injuries and illnesses, has ordered an update of their existing PExA 2.0 instrument.
Tomas Gustafsson, CEO of PExA, comments:
- We are very pleased and grateful to continue earning the trust of customers who have used PExA for many years. By enabling non-invasive sampling, lung changes can be studied over time in a wide range of groups to identify biomarkers indicating everything from changes caused by occupational exposure to lung cancer, in ways that were previously not possible.
For further information, please contact:
Tomas Gustafsson, Email: info@pexa.se
About PExA AB:
PExA AB (556956-9246) has developed the PExA 2.1, a patented research instrument that helps researchers intelligently collect biological samples from the smallest airways through a simple exhalation maneuver. PExA’s technology is currently used by prominent research groups in several different countries and research with the instrument has resulted in approximately 50 scientific publications, which serve as reference material for PExA’s method. The company’s long-term goal is to market and sell diagnostic instruments for popular diseases (e.g. lung cancer and COPD) to be used globally for diagnosis or general screening at facilities where care is offered. The company intends at the time it is relevant to sell to clinics to have developed more patient-friendly, flexible and commercial products, which means that PExA addresses a significantly wider market, which today includes several million patients globally.
PExA’s B share is listed on the Spotlight Stock Market.